StocksFundsScreenerSectorsWatchlists
ISPC

ISPC - iSpecimen Inc. Stock Price, Fair Value and News

0.23USD-0.02 (-8.00%)Delayed as of 28 Mar 2024, 12:38 pm ET

Market Summary

ISPC
USD0.23-0.02
Delayedas of 28 Mar 2024, 12:38 pm
-8.00%

ISPC Stock Price

View Fullscreen

ISPC RSI Chart

ISPC Valuation

Market Cap

2.3M

Price/Earnings (Trailing)

-0.2

Price/Sales (Trailing)

0.21

EV/EBITDA

-0.32

Price/Free Cashflow

-0.39

ISPC Price/Sales (Trailing)

ISPC Profitability

EBT Margin

-53.26%

Return on Equity

-113.95%

Return on Assets

-70.16%

Free Cashflow Yield

-256.49%

ISPC Fundamentals

ISPC Revenue

Revenue (TTM)

10.9M

Rev. Growth (Yr)

-42.11%

Rev. Growth (Qtr)

-41.08%

ISPC Earnings

Earnings (TTM)

-11.1M

Earnings Growth (Yr)

-42.29%

Earnings Growth (Qtr)

-45.56%

Breaking Down ISPC Revenue

52 Week Range

0.222.05
(Low)(High)

Last 7 days

-35.1%

Last 30 days

-46.7%

Last 90 days

-52.9%

Trailing 12 Months

-72.4%

How does ISPC drawdown profile look like?

ISPC Financial Health

Current Ratio

1.36

ISPC Investor Care

Shares Dilution (1Y)

3.59%

Diluted EPS (TTM)

-1.22

Historical Charts for Stock Metrics

Get all data in R, Python etc through our Historical Stock Data APIs
Net sales
YearQ1Q2Q3Q4
202311.0M11.9M12.1M10.9M
202210.7M10.4M10.3M10.5M
20219.4M10.8M11.3M11.1M
202005.6M6.9M8.2M
20190004.3M

Tracking the Latest Insider Buys and Sells of iSpecimen Inc.

Filter Transactions
Datesorted ascendingNameBuy/Sell$ ValueAvg. Price# SharesTitle
Sep 14, 2023
bielak benjamin
bought
12,960
0.72
18,000
chief info officer & secretary
May 31, 2023
curley tracy
bought
5,500
1.25
4,400
ceo, cfo and treasurer
Jan 17, 2023
mullan jill
acquired
66,637
1.00
66,637
-
Jan 06, 2023
ianelli christopher
acquired
845
1.00
845
-
Jan 01, 2023
basile joseph j.
acquired
-
-
63.00
-
Jan 01, 2023
mullan jill
acquired
-
-
92.00
-
Jan 01, 2023
ianelli christopher
acquired
-
-
92.00
-
Jan 01, 2023
ross andrew l.
acquired
-
-
125
-
Jan 01, 2023
gullans steven r. ph.d.
acquired
-
-
125
-
Jan 01, 2023
brooks john l. iii
acquired
-
-
125
-

1–10 of 50

Which funds bought or sold ISPC recently?

View All Details
Datesorted ascendingFund NameType% Chg$ Change$ Held% Portfolio
Mar 11, 2024
VANGUARD GROUP INC
reduced
-10.96
-26,241
67,131
-%
Feb 14, 2024
Schonfeld Strategic Advisors LLC
reduced
-10.26
-3,331
8,759
-%
Feb 14, 2024
SUSQUEHANNA INTERNATIONAL GROUP, LLP
sold off
-100
-14,117
-
-%
Feb 14, 2024
MILLENNIUM MANAGEMENT LLC
new
-
10,757
10,757
-%
Feb 14, 2024
CITADEL ADVISORS LLC
new
-
19,428
19,428
-%
Feb 13, 2024
GEODE CAPITAL MANAGEMENT, LLC
unchanged
-
-4,596
19,272
-%
Feb 13, 2024
NORTHERN TRUST CORP
unchanged
-
-1,648
6,911
-%
Feb 13, 2024
Tower Research Capital LLC (TRC)
reduced
-1.48
-394
1,539
-%
Feb 13, 2024
BlackRock Inc.
unchanged
-
-6,769
28,384
-%
Feb 13, 2024
RENAISSANCE TECHNOLOGIES LLC
new
-
5,000
5,000
-%

1–10 of 18

Are Funds Buying or Selling ISPC?

Are funds buying ISPC calls or puts?
Calls
Puts
No. of funds holding Calls - Puts
Net Call Options
No. of funds that own ISPC
No. of Funds

Unveiling iSpecimen Inc.'s Major ShareHolders

Date FiledName of FilerPercent of ClassNo. of SharesForm Type
Feb 13, 2024
obf investments, llc
9.3%
841,981
SC 13G/A
Apr 17, 2023
ross andrew l.
797%
1,336,730
SC 13D
Feb 13, 2023
obf investments, llc
9.4%
841,981
SC 13G/A
Jan 12, 2023
empery asset management, lp
4.68%
437,500
SC 13G/A
Dec 27, 2022
wolf james g.
9.03%
790,730
SC 13G/A
Sep 28, 2022
wolf james g.
6.13%
544,250
SC 13G
Feb 14, 2022
obf investments, llc
9.6%
841,981
SC 13G
Feb 14, 2022
bleichroeder lp
3.41%
342,180
SC 13G/A
Feb 07, 2022
ross andrew l.
15.23%
1,329,759
SC 13G

Recent SEC filings of iSpecimen Inc.

View All Filings
Date Filed Form Type Document
Mar 26, 2024
8-K
Current Report
Mar 26, 2024
3
Insider Trading
Mar 14, 2024
8-K
Current Report
Mar 13, 2024
10-K
Annual Report
Mar 05, 2024
8-K
Current Report
Mar 05, 2024
424B5
Prospectus Filed
Feb 15, 2024
8-K
Current Report
Feb 13, 2024
SC 13G/A
Major Ownership Report
Feb 08, 2024
5
Insider Trading
Dec 21, 2023
8-K
Current Report

Peers (Alternatives to iSpecimen Inc.)

NameMkt Capsorted ascendingRevenuePrice %, 1MReturns, 1YP/EP/SRev 1-YrInc 1-Yr
LARGE-CAP
184.1B
23.9B
1.92% 4.87%
38.82
7.71
-10.33% -33.23%
44.8B
3.7B
-4.47% 16.47%
53.05
12.25
8.72% 24.44%
43.2B
6.7B
9.35% 8.66%
34.96
6.42
-2.81% -6.58%
14.5B
9.3B
4.27% -4.49%
16.99
1.57
-6.38% -9.73%
13.8B
4.1B
11.27% 27.86%
29.14
3.35
3.86% -2.39%
12.4B
1.9B
4.38% 126.16%
43.86
6.58
29.17% 15.26%
12.1B
2.5B
1.85% -6.90%
-59.47
4.86
19.93% 67.26%
10.9B
1.1B
31.87% 65.38%
-25.12
10.09
31.99% 20.63%
MID-CAP
3.3B
918.7M
-13.78% -12.36%
284.21
3.64
45.66% 172.57%
2.2B
563.9M
-23.06% -38.26%
-4.56
3.88
25.45% 26.76%
SMALL-CAP
544.7M
280.3M
17.34% 2.80%
-2.86
1.94
-12.89% -148.37%
89.4M
31.2M
-3.36% -85.17%
-1.01
2.86
5.03% -1.81%
35.5M
9.2M
-24.43% -39.17%
-1.95
3.86
16.43% 46.89%
7.3M
9.0M
-21.88% -54.13%
-1.01
0.81
-53.31% 2.21%
183.8K
25.9M
-50.00% -94.83%
-0.01
0.01
-57.78% -93.11%

iSpecimen Inc. News

Latest updates
Yahoo Finance • 15 Mar 2024 • 02:48 pm
Investing.com Australia • 15 Mar 2024 • 02:01 am
Marketscreener.com • 14 Mar 2024 • 12:01 pm
Defense World • 11 Mar 2024 • 06:31 am
Marketscreener.com • 05 Mar 2024 • 08:00 am

iSpecimen Inc. Earnings Report: Key Takeaways & Analysis

Income Statement (Last 12 Months)
Income Statement (Quarterly)
Description(%) Q/Q2023Q42023Q32023Q22023Q12022Q42022Q32022Q22022Q12021Q42021Q32021Q22021Q12020Q42020Q32020Q22019Q4
Revenue-41.1%1,636,7812,777,7513,501,7692,950,1972,827,4832,583,4122,606,8092,518,6602,549,0862,718,5342,903,8762,963,8072,717,7312,250,1471,504,569-
Costs and Expenses9.5%5,446,1194,971,8315,186,9635,492,6205,103,1715,684,4714,923,6954,877,0484,544,0844,177,6074,432,4073,906,4513,652,1812,973,2261,809,575-
  S&GA Expenses17.1%1,050,921897,433977,748962,169914,725832,625950,563747,432732,658513,107647,592529,387477,666506,641367,617-
EBITDA Margin-15.3%-0.52-0.45-0.46-0.50-0.52-0.54-0.53-0.42-0.33-0.27-0.12-0.24-0.31-0.45-0.55-
Interest Expenses0.0%4,4664,4653,5353,535-58,59142,27338,04840,13375,9221,133,479853,147579,098469,477459,005-
Earnings Before Taxes-----------1,553,023-1,394,914--1,593,544-1,246,469-174,237-
EBT Margin-11.0%-0.53-0.48-0.49-0.53-0.55-0.56-0.56-0.54-0.52-0.51-0.41-0.49-0.57-0.71-0.87-
Net Income-45.6%-3,072,961-2,111,101-3,483,614-2,431,812-2,159,681-3,095,690-2,606,809-2,383,742-2,050,387-1,553,023-1,394,914-3,963,491-1,593,544-1,246,469-174,092-
Net Income Margin-20.9%-1.02-0.84-0.94-0.94-0.97-0.99-0.83-0.69-0.80-0.75-0.76-0.74-0.57-0.69-0.85-
Free Cashflow121.1%345,141-1,639,506-1,699,056-2,833,607-207,354-2,256,389-1,978,061-1,375,916-1,319,709-6,080,166------
Balance Sheet
(In Thousands)
Balance Sheet
(In Thousands)
(*) denotes actual numbers (not divided by Thousands)
Description(%) Q/Q2023Q42023Q32023Q22023Q12022Q42022Q32022Q22022Q12021Q42021Q32021Q22021Q12020Q42019Q4
Assets-2.9%15,81916,29517,57021,93924,61827,94030,39733,28735,72017,62219,60512,9076,2104,215
  Current Assets-9.7%8,2399,12710,97115,96019,67624,23627,13130,15132,94814,89916,919-3,4721,581
    Cash Equivalents-13.9%2,3442,7222,0053,76315,30920,65823,69126,09927,7399,79113,18435569654.00
  Net PPE-12.6%12814616419522619.0024.0028.0033.0045.0056.00-76.00120
Liabilities69.3%6,0783,5892,8603,8554,3085,5165,1005,6205,9285,5318,92615,62022,31515,760
  Current Liabilities72.0%6,0493,5172,8603,8554,2812,8332,0292,0472,5052,1035,926-22,13615,760
Shareholder's Equity-23.3%9,74112,70614,71118,08420,30922,42325,29827,66729,79212,09110,679---
  Retained Earnings-5.5%-59,364-56,291-54,180-50,697-48,265-46,105-43,009-40,403-38,019-35,969-34,415--29,057-24,405
  Additional Paid-In Capital0.2%69,10468,99668,89068,76268,57468,52868,30768,07067,81048,05945,095-1,7801,687
Shares Outstanding0.1%9,0839,0749,0639,0228,9268,8798,7948,7658,7333,1901,612936936-
Cashflow (Last 12 Months)
(In Thousands)
Cashflow (Quarterly)
(In Thousands)
(*) denotes actual numbers (not divided by Thousands)
Description(%) Q/Q2023Q42023Q32023Q22023Q12022Q42022Q32022Q22022Q12021Q42021Q32021Q22021Q12020Q42020Q32020Q22019Q4
Cashflow From Operations121.1%345-1,633-1,693-2,825-207-2,256-1,978-1,375-1,319-6,080-3,142-126-24.65-319--
  Share Based Compensation1.7%10810612512145.0022022918417240028.0022.0012.0029.00--
Cashflow From Investing-130.8%-7232,351-67.97-8,788-1,641-772-438-339-304-290-228-214-236-273--
Cashflow From Financing---3.0068.00-3,499-4.978.0075.0019,5722,977---250--

ISPC Income Statement

2023-12-31
Condensed Statements of Operations and Comprehensive Loss - USD ($)
12 Months Ended
Dec. 31, 2023
Dec. 31, 2022
Condensed Statements of Operations  
Revenue$ 9,928,184$ 10,402,303
Operating expenses:  
Cost of revenue4,820,2684,756,965
Technology3,566,9172,656,287
Sales and marketing3,955,9743,445,344
Supply development1,030,403801,125
Fulfillment1,788,8791,995,937
General and administrative5,935,0926,932,727
Total operating expenses21,097,53320,588,385
Loss from operations(11,169,349)(10,186,082)
Other income (expense), net  
Interest expense(16,001)(238,963)
Interest income339,750169,345
Interest and penalties on sales tax liability(214,784) 
Other income (expense), net(39,104)9,778
Total other income (expense), net69,861(59,840)
Net loss(11,099,488)(10,245,922)
Unrealized gains on available-for-sale securities840 
Total other comprehensive income840 
Comprehensive loss$ (11,098,648)$ (10,245,922)
Net loss per share  
Basic (in dollars per share)$ (1.23)$ (1.16)
Diluted (in dollars per share)$ (1.23)$ (1.16)
Weighted average shares of common stock outstanding  
Basic (in shares)9,041,3418,844,307
Diluted (in shares)9,041,3418,844,307

ISPC Balance Sheet

2023-12-31
Condensed Balance Sheets - USD ($)
Dec. 31, 2023
Dec. 31, 2022
Current assets:  
Cash and cash equivalents$ 2,343,666$ 15,308,710
Available-for-sale securities2,661,9320
Accounts receivable - unbilled2,212,5382,327,789
Accounts receivable, net of allowance for doubtful accounts of $520,897 and $230,999 at December 31, 2023 and 2022, respectively728,3881,597,915
Prepaid expenses and other current assets292,079300,434
Tax credit receivable 140,873
Total current assets8,238,60319,675,721
Property and equipment, net127,787225,852
Internally developed software, net6,323,0344,503,787
Other intangible assets, net908,255 
Operating lease right-of-use asset193,857184,692
Security deposits27,60127,601
Total assets15,819,13724,617,653
Current liabilities:  
Accounts payable3,925,4382,459,063
Accrued expenses1,540,6071,531,238
Operating lease - current obligation167,114158,451
Deferred revenue415,771132,335
Total current liabilities6,048,9304,281,087
Operating lease long - term obligation29,13027,396
Total liabilities6,078,0604,308,483
Stockholders' equity  
Common stock, $0.0001 par value, 200,000,000 shares authorized, 9,114,371 issued, and 9,083,371 outstanding at December 31, 2023 and 8,956,808 issued and 8,925,808 outstanding at December 31, 2022908892
Additional paid-in capital69,104,31368,573,774
Treasury stock, 31,000 shares at December 31, 2023 and 2022, at cost(172)(172)
Accumulated other comprehensive income840 
Accumulated deficit(59,364,812)(48,265,324)
Total stockholders' equity9,741,07720,309,170
Total liabilities and stockholders' equity$ 15,819,137$ 24,617,653
ISPC
iSpecimen Inc. provides technology that connects life science researchers who need human biofluids, tissues, and living cells for their research with biospecimens available in healthcare provider organizations worldwide. Its cloud-based technology enables scientists to search for specimens and patients across a network of hospitals, labs, biobanks, blood centers, and other healthcare organizations. The company develops and operates iSpecimen Marketplace, a proprietary online marketplace platform that connects medical researchers who need access to subjects, samples, and data with hospitals, laboratories, and other organizations who have access to them. It serves biopharmaceutical companies, in vitro diagnostic companies, and government/academic institutions. The company was incorporated in 2009 and is headquartered in Lexington, Massachusetts.
 CEO
 WEBSITEispecimen.com
 EMPLOYEES75

iSpecimen Inc. Frequently Asked Questions


What is the ticker symbol for iSpecimen Inc.? What does ISPC stand for in stocks?

ISPC is the stock ticker symbol of iSpecimen Inc.. Every public company that trades on a stock exchange gets a ticker symbol.

What is the market capital of iSpecimen Inc. (ISPC)?

As of Wed Mar 27 2024, market cap of iSpecimen Inc. is 2.27 Million. The market capitalization is calculated by multiplying the stock price with the number of shares outstanding.

What is the fair value of ISPC stock?

You can check ISPC's fair value in chart for subscribers.

What is the fair value of ISPC stock?

You can check ISPC's fair value in chart for subscribers. The fair value of iSpecimen Inc. is provided for various growth and macro-economic scenarios from very pessimiatic to very optimistic assumptions. These fair values are estimates from Grufity's Fair Value model based on company's past performance. However, past performance of iSpecimen Inc. is no guarantee of future performance. These fairvalue estimates should only be used as one of the inputs in your stock analysis. We provide model's historical fair value estimates for ISPC so that you know how good or bad the model has been in the past so you can discard it if needed. There are others that provide fair values of stocks such as wallmine, finbox, gurufocus and finviz. Most provide point in time estimates. We provide a history of our models fair value estimates so that you can get a sense of it's usefulness. Otherwise this data point is of little use.

Is iSpecimen Inc. a good stock to buy?

The fair value guage provides a quick view whether ISPC is over valued or under valued. Whether iSpecimen Inc. is cheap or expensive depends on the assumptions which impact iSpecimen Inc.'s fair value. We provide several scenarios of inflation and growth to encompass these range of assumptions for ISPC.

What is iSpecimen Inc.'s Price to Earnings (PE) and Price to sales (PS) ratio?

As of Wed Mar 27 2024, ISPC's PE ratio (Price to Earnings) is -0.2 and Price to Sales (PS) ratio is 0.21. The price to earnings and price to sales ratio are two most important valuation metrics for any company. PE ratio tell us the number of years of earnings investors are ready to pay for owning the company. Historically, S&P500 price to earnings ratio has fallen below 12 during periods of gloom and gone past 30 during periods of euphoria. ISPC PE ratio will change depending on the future growth rate expectations of investors.